Innovative drug development for headache disorders /
Innovative drug development for headache disorders /
edited by Jes Olesen, Nabih Ramadan.
- Oxford ; New York : Oxford University Press, 2008.
- 1 online resource (xii, 227 pages) : illustrations
- Frontiers in headache research series ; v. 16 .
- Frontiers in headache research ; v. 16. .
Includes bibliographical references and index.
Effectiveness of different steroid dosage in Tolosa-Hunt syndrome with different phenotypes: some critical points about the new International Headache Society classification / E. Marchioni [and others] -- Discussion summary: trial methodology / Jes Olesen -- Inducible nitric oxide synthase and development of new migraine treatments / Boris A. Chizh -- Mechanisms of cortical spreading depression as targets for migraine therapy / Kevin C. Brennan and Andrew C. Charles -- Tonabersat / Peter R. Blower and Paul C. Sharpe -- Discussion summary: nitric oxide and spreading depression modulators / Nabih Ramadan -- Calcitonin gene-related peptide: relevance for migraine / Jes Olesen and Inger Jansen-Olesen. KATP channels and migraine / Inger Jansen-Olesen and Kenneth Beri Ploug -- Antiepileptic drugs and migraine / Michael A. Rogawski -- Discussion summary : ion channel modulators and antiepileptics / Pramod R. Saxena -- Innovative drug development for headache disorders : glutamate / Kirk W. Johnson [and others] -- The modulation of TRPV1 channels by cannabinoid1 receptors / Beatriz Fioravanti and Todd W. Vanderah -- Future targets for headache therapy: prostanoids / Christian Waeber -- Role of anandamide in the modulation of nitroglycerin-induced hyperalgesia: a study in the rat / Cristina Tassorelli [and others].
Migraine treatment improved considerably with the advent of the 'triptans' in the 1990s. While the drugs used previously for headache treatment had efficacy, some compounds had bothersome side effects and their overuse could lead to severe complications. In the early days of the triptans, it was widely presumed that migraine was no longer a treatment problem. However, it has gradually been recognized that a significant proportion of patients are not responsive to triptans or do not tolerate them.
9780191564628 (electronic bk.) 0191564621 (electronic bk.)
GBA889279 bnb
101474374 DNLM 014669623 Uk
Headache--Chemotherapy.
Analgesics.
Drug development.
Headache Disorders--drug therapy
Headache Disorders--prevention & control
Analgesics
Céphalée--Chimiothérapie.
Analgésiques.
Médicaments--Développement.
HEALTH & FITNESS--Diseases--Nervous System (incl. Brain)
MEDICAL--Neurology.
Analgesics.
Drug development.
Headache--Chemotherapy.
Céphalées--traitement médicamenteux.
Céphalées--prévention et contrôle.
Migraine--Chimiothérapie.
Analgésiques.
Electronic books.
RC392 / .I558 2008eb
616.8/491061
W1 / FR945YD v.16 2008 WL 342 / I58 2008
Includes bibliographical references and index.
Effectiveness of different steroid dosage in Tolosa-Hunt syndrome with different phenotypes: some critical points about the new International Headache Society classification / E. Marchioni [and others] -- Discussion summary: trial methodology / Jes Olesen -- Inducible nitric oxide synthase and development of new migraine treatments / Boris A. Chizh -- Mechanisms of cortical spreading depression as targets for migraine therapy / Kevin C. Brennan and Andrew C. Charles -- Tonabersat / Peter R. Blower and Paul C. Sharpe -- Discussion summary: nitric oxide and spreading depression modulators / Nabih Ramadan -- Calcitonin gene-related peptide: relevance for migraine / Jes Olesen and Inger Jansen-Olesen. KATP channels and migraine / Inger Jansen-Olesen and Kenneth Beri Ploug -- Antiepileptic drugs and migraine / Michael A. Rogawski -- Discussion summary : ion channel modulators and antiepileptics / Pramod R. Saxena -- Innovative drug development for headache disorders : glutamate / Kirk W. Johnson [and others] -- The modulation of TRPV1 channels by cannabinoid1 receptors / Beatriz Fioravanti and Todd W. Vanderah -- Future targets for headache therapy: prostanoids / Christian Waeber -- Role of anandamide in the modulation of nitroglycerin-induced hyperalgesia: a study in the rat / Cristina Tassorelli [and others].
Migraine treatment improved considerably with the advent of the 'triptans' in the 1990s. While the drugs used previously for headache treatment had efficacy, some compounds had bothersome side effects and their overuse could lead to severe complications. In the early days of the triptans, it was widely presumed that migraine was no longer a treatment problem. However, it has gradually been recognized that a significant proportion of patients are not responsive to triptans or do not tolerate them.
9780191564628 (electronic bk.) 0191564621 (electronic bk.)
GBA889279 bnb
101474374 DNLM 014669623 Uk
Headache--Chemotherapy.
Analgesics.
Drug development.
Headache Disorders--drug therapy
Headache Disorders--prevention & control
Analgesics
Céphalée--Chimiothérapie.
Analgésiques.
Médicaments--Développement.
HEALTH & FITNESS--Diseases--Nervous System (incl. Brain)
MEDICAL--Neurology.
Analgesics.
Drug development.
Headache--Chemotherapy.
Céphalées--traitement médicamenteux.
Céphalées--prévention et contrôle.
Migraine--Chimiothérapie.
Analgésiques.
Electronic books.
RC392 / .I558 2008eb
616.8/491061
W1 / FR945YD v.16 2008 WL 342 / I58 2008